Progress in the Management of Malignant Pleural Mesothelioma in 2017

Amanda J. McCambridge, Andrea Napolitano, Aaron S. Mansfield, Dean A. Fennell, Yoshitaka Sekido, Anna K. Nowak, Thanyanan Reungwetwattana, Weimin Mao, Harvey I. Pass, Michele Carbone, Haining Yang, Tobias Peikert

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.

Original languageEnglish
Pages (from-to)606-623
Number of pages18
JournalJournal of Thoracic Oncology
Volume13
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

BRCA1 Protein
Immunotherapy
Polycomb Repressive Complex 2
Argininosuccinate Synthase
Neoplasms
Death Domain Receptors
Tumor Microenvironment
Asbestos
Therapeutics
Adenosine
Malignant Mesothelioma
Ligands
Incidence
Genes

Cite this

McCambridge, A. J., Napolitano, A., Mansfield, A. S., Fennell, D. A., Sekido, Y., Nowak, A. K., ... Peikert, T. (2018). Progress in the Management of Malignant Pleural Mesothelioma in 2017. Journal of Thoracic Oncology, 13(5), 606-623. https://doi.org/10.1016/j.jtho.2018.02.021
McCambridge, Amanda J. ; Napolitano, Andrea ; Mansfield, Aaron S. ; Fennell, Dean A. ; Sekido, Yoshitaka ; Nowak, Anna K. ; Reungwetwattana, Thanyanan ; Mao, Weimin ; Pass, Harvey I. ; Carbone, Michele ; Yang, Haining ; Peikert, Tobias. / Progress in the Management of Malignant Pleural Mesothelioma in 2017. In: Journal of Thoracic Oncology. 2018 ; Vol. 13, No. 5. pp. 606-623.
@article{12ee23c1e55544c1be773f526b4067a3,
title = "Progress in the Management of Malignant Pleural Mesothelioma in 2017",
abstract = "Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.",
keywords = "BAP1, Immunotherapy, Mesothelin, Mesothelioma, Review, Therapy",
author = "McCambridge, {Amanda J.} and Andrea Napolitano and Mansfield, {Aaron S.} and Fennell, {Dean A.} and Yoshitaka Sekido and Nowak, {Anna K.} and Thanyanan Reungwetwattana and Weimin Mao and Pass, {Harvey I.} and Michele Carbone and Haining Yang and Tobias Peikert",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.jtho.2018.02.021",
language = "English",
volume = "13",
pages = "606--623",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Academic Press",
number = "5",

}

McCambridge, AJ, Napolitano, A, Mansfield, AS, Fennell, DA, Sekido, Y, Nowak, AK, Reungwetwattana, T, Mao, W, Pass, HI, Carbone, M, Yang, H & Peikert, T 2018, 'Progress in the Management of Malignant Pleural Mesothelioma in 2017' Journal of Thoracic Oncology, vol. 13, no. 5, pp. 606-623. https://doi.org/10.1016/j.jtho.2018.02.021

Progress in the Management of Malignant Pleural Mesothelioma in 2017. / McCambridge, Amanda J.; Napolitano, Andrea; Mansfield, Aaron S.; Fennell, Dean A.; Sekido, Yoshitaka; Nowak, Anna K.; Reungwetwattana, Thanyanan; Mao, Weimin; Pass, Harvey I.; Carbone, Michele; Yang, Haining; Peikert, Tobias.

In: Journal of Thoracic Oncology, Vol. 13, No. 5, 01.05.2018, p. 606-623.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Progress in the Management of Malignant Pleural Mesothelioma in 2017

AU - McCambridge, Amanda J.

AU - Napolitano, Andrea

AU - Mansfield, Aaron S.

AU - Fennell, Dean A.

AU - Sekido, Yoshitaka

AU - Nowak, Anna K.

AU - Reungwetwattana, Thanyanan

AU - Mao, Weimin

AU - Pass, Harvey I.

AU - Carbone, Michele

AU - Yang, Haining

AU - Peikert, Tobias

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.

AB - Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.

KW - BAP1

KW - Immunotherapy

KW - Mesothelin

KW - Mesothelioma

KW - Review

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85046378485&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.02.021

DO - 10.1016/j.jtho.2018.02.021

M3 - Review article

VL - 13

SP - 606

EP - 623

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 5

ER -

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK et al. Progress in the Management of Malignant Pleural Mesothelioma in 2017. Journal of Thoracic Oncology. 2018 May 1;13(5):606-623. https://doi.org/10.1016/j.jtho.2018.02.021